ÂÜÀòÂÒÂ×

Michel Sadelain, MD, PhD is the Scientific Co-Founder and President of the Scientific Advisory Board at Mnemo. He is the founding director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center (MSK), where he holds the Stephen and Barbara Friedman Chair, a member of the department of Medicine and of the Immunology program of the Sloan Kettering Institute, and a professor of Immunology at Weill-Cornell Medical College. Following his post-doctoral research at the Whitehead Institute at MIT, he joined MSK in 1994. Dr. Sadelain has made several key contributions to the emergence and success of CD19 chimeric antigen receptor (CAR) therapy. His research has contributed to all facets of CAR therapy, including T cell engineering methodologies (via retroviral vectors or gene editing), CAR design (dual-signaling receptor concept, known as second generation CAR), target identification (most notably CD19), T cell manufacturing (GMP processes, in collaboration with Dr. Isabelle Rivière at MSK) and clinical translation (in acute lymphoblastic leukemia and other cancers). Dr. Sadelain received his M.D. from the University of Paris (Pierre et Marie Curie) in 1984 and his Ph.D. from the University of Alberta in 1989.